Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Molecular subtypes in diffuse large B-cell lymphoma

Christian Gisselbrecht • 12 Jun 2015
EHA 2015
Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. At the 20th Congress of the European Hematology Association (EHA), Christian Gisselbrecht, MD, of Paris Diderot University, Paris, France, explains the clinical significance of molecularly subtyping DLBCL as germinal center B-cell (GCB) or non-GCB (activated B cell-like).

More from Christian Gisselbrecht

2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
1:30
Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II study
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals